JAGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jaguar Health Inc (JAGX) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available. The company is facing significant financial challenges, including declining revenue, widening net losses, and poor EPS performance. Additionally, there are no strong technical or trading signals to suggest a favorable entry point, and the stock lacks positive catalysts or strong institutional support.
The technical indicators for JAGX are bearish. The moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downward trend. The RSI is neutral at 37.481, and the MACD histogram is positive but contracting, showing no clear momentum. The stock's price is below key pivot levels, with support at 0.329 and resistance at 0.392.
Additionally, the FDA has renewed approval for Canalevia-CA1 until December 2026.
The company reported a Q4 2025 revenue decline of 8.6% YoY and a widening net loss of $53.6 million, raising concerns about profitability and market demand. Financial performance in Q3 2025 also showed declining revenue (-0.80% YoY), worsening net income (-3.57% YoY), and a significant drop in EPS (-76.11% YoY).
Jaguar Health's financials are weak. In Q4 2025, revenue dropped to $3.2 million (-8.6% YoY), and the net loss widened to $53.6 million. In Q3 2025, revenue dropped by -0.80% YoY, net income declined by -3.57% YoY, and EPS fell sharply by -76.11% YoY. Gross margin increased slightly to 82.74%, but this does not offset the overall negative financial performance.
No recent analyst ratings or price target changes are available for JAGX.
